Study of golidocitinib plus sintilimab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer that is advanced or has spread.
- You have not had certain genetic mutations (EGFR or ALK) in your cancer.
- You are generally able to care for yourself (ECOG performance status 0-1).
- For some parts of the study, you must not have had prior treatment for advanced disease, and your cancer must have a specific level of PD-L1 protein.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This study tests a new drug called tolododekin alfa combined with an approved immunotherapy drug for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.